1-2 of 2
Yilin Jiang
Close
Sort by
Journal Articles

Optimized cytogenetic risk-group stratification of KMT2A -rearranged pediatric acute myeloid leukemia

Romy E. van Weelderen, Christine J. Harrison, Kim Klein, Yilin Jiang, Jonas Abrahamsson, Todd Alonzo, Richard Aplenc, Nira Arad-Cohen, Emmanuelle Bart-Delabesse, Barbara Buldini, Barbara De Moerloose, Michael N. Dworzak, Sarah Elitzur, José M. Fernández Navarro, Alan Gamis, Robert B. Gerbing, Bianca F. Goemans, Hester A. de Groot-Kruseman, Erin Guest, Shau-Yin Ha, Henrik Hasle, Charikleia Kelaidi, Hélène Lapillonne, Guy Leverger, Franco Locatelli, Takako Miyamura, Ulrika Norén-Nyström, Sophia Polychronopoulou, Mareike Rasche, Jeffrey E. Rubnitz, Jan Stary, Anne Tierens, Daisuke Tomizawa, C. Michel Zwaan, Gertjan J. L. Kaspers
Journal: Blood Advances
Blood Adv (2024) 8 (12): 3200–3213.
https://doi.org/10.1182/bloodadvances.2023011771
Published: 2024
Includes: Supplemental data
Journal Articles

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia

Linde Dekker, Friso G. Calkoen, Yilin Jiang, Hilly Blok, Saskia R. Veldkamp, Coco De Koning, Maike Spoon, Rick Admiraal, Peter Hoogerbrugge, Britta Vormoor, H. Josef Vormoor, Henk Visscher, Marc Bierings, Marieke Van Der Vlugt, Harm Van Tinteren, A. Laura Nijstad, Alwin D. R. Huitema, Kim C. M. Van Der Elst, Rob Pieters, Caroline A. Lindemans, Stefan Nierkens
Journal: Blood Advances
Blood Adv (2022) 6 (7): 1969–1976.
https://doi.org/10.1182/bloodadvances.2021006700
Published: 2022
Includes: Supplemental data